Status: Recruiting
A Study Evaluating the Effects of Itraconazole or Rifampin on the Pharmacokinetic Characteristics of Rocbrutinib Tablet
This is a phase I, open-label, two-part, fixed-sequence drug interaction study conducted to evaluate the effects of concomitant use of the potent CYP3A4 inhibitor itraconazole or the CYP3A4 inducer rifampin on the pharmacokinetics of Rocbrutinib in healthy subjects.
Participants needed: 28
Trial details
Phase: Phase 1Age: 18-45Biological sex: AllType: InterventionalSponsor: Guangzhou Lupeng Pharmaceutical Company LTD.Updated: Mar 9, 2026Locations: 1
Eligibility criteria
Subjects had no history of serious digestive system (such as inflammatory bowel... [+5]
Abnormalities in screening tests, such as vital signs, physical examination, or... [+17]